Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Silymarin: A Phytoconstituent with Significant Therapeutic Potential - A Narrative Review

Author(s): Sahil Sharma, Pravin Kumar*, Mahendra Singh Ashawat, Vinay Pandit, Chandrapal Singh Verma and Dinesh Kumar Sharma

Volume 18, Issue 2, 2023

Published on: 18 January, 2023

Page: [89 - 97] Pages: 9

DOI: 10.2174/1574885518666221227100052

Price: $65

Abstract

Silymarin, is a phytoactive constituent isolated from the fruits and seeds of Silybum marianum L Gaetn.), also called milk thistle belonging to the family of Asteracease. The phytoactive has been used to treat several physiological disorders. The objective of this manuscript was to review the therapeutic prospective of silymarin due to its ability to treat several physiological disorders. The databases such as Pubmed, Elsevier, and Google Scholar were reviewed for the investigations or reviews published related to the title. The discussion is focused on the immunomodulatory, chemopreventive, and anti-inflammatory mechanisms of silymarin in various metabolic and dermatological disorders. In addition, the review discusses the different therapeutic potentials of silymarin such as the management of the liver disorder, skin carcinogenesis, cardiovascular disorders, diabetes mellitus, neurodegenerative disorders, and several dermatological disorders such as melasma, anti-aging, acne, rosacea, atopic dermatitis, and psoriasis. Silymarin is safe even with a dose higher than the therapeutic dose. Silymarin had good potential for the safe and effective treatment of numerous metabolic and dermatological disorders.

« Previous
Graphical Abstract

[1]
Wagner H, Diesel P, Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung 1974; 24(4): 466-71.
[PMID: 4408125]
[2]
Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology 1999; 30(4): 1099-104.
[http://dx.doi.org/10.1002/hep.510300437] [PMID: 10498665]
[3]
Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9(1): 105-13.
[http://dx.doi.org/10.1016/0168-8278(89)90083-4] [PMID: 2671116]
[4]
Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982; 17(4): 517-21.
[http://dx.doi.org/10.3109/00365528209182242] [PMID: 6753109]
[5]
Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61(14): 2035-63.
[http://dx.doi.org/10.2165/00003495-200161140-00003] [PMID: 11735632]
[6]
Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011; 14(4): 308-17.
[PMID: 23492971]
[7]
Ullah H, Khan H. Anti-Parkinson potential of silymarin: Mechanistic insight and therapeutic standing. Front Pharmacol 2018; 9(1): 422.
[http://dx.doi.org/10.3389/fphar.2018.00422] [PMID: 29755356]
[8]
Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006; 124(5): 491-504.
[PMID: 17213517]
[9]
Lorenz D, Lücker PW, Mennicke WH, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984; 6(10): 655-61.
[PMID: 6513680]
[10]
Lee DYW, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod 2003; 66(9): 1171-4.
[http://dx.doi.org/10.1021/np030163b] [PMID: 14510591]
[11]
Kuki Á, Nagy L, Deák G, Nagy M, Zsuga M, Kéki S. Identification of silymarin constituents: An improved HPLC-MS method. Chromatographia 2012; 75(3-4): 175-80.
[http://dx.doi.org/10.1007/s10337-011-2163-7]
[12]
Graf TN, Cech NB, Polyak SJ, Oberlies NH. A validated UHPLC-tandem mass spectrometry method for quantitative analysis of flavonolignans in milk thistle (Silybum marianum) extracts. J Pharm Biomed Anal 2016; 126: 26-33.
[http://dx.doi.org/10.1016/j.jpba.2016.04.028] [PMID: 27136284]
[13]
Pizzino G, Irrera N, Cucinotta M, et al. Oxidative Stress: Harms and benefits for human health. Oxid Med Cell Longev 2017; 2017: 1-13.
[http://dx.doi.org/10.1155/2017/8416763] [PMID: 28819546]
[14]
Katiyar SK, Mantena SK, Meeran SM. Silymarin protects epidermal keratinocytes from ultraviolet radiation-induced apoptosis and DNA damage by nucleotide excision repair mechanism. PLoS One 2011; 6(6): e21410.
[http://dx.doi.org/10.1371/journal.pone.0021410] [PMID: 21731736]
[15]
Kumar R, Deep G, Agarwal R. An overview of ultraviolet B radiation-induced skin cancer chemoprevention by silibinin. Curr Pharmacol Rep 2015; 1(3): 206-15.
[http://dx.doi.org/10.1007/s40495-015-0027-9] [PMID: 26097804]
[16]
Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem Photobiol 2008; 84(3): 539-49.
[http://dx.doi.org/10.1111/j.1751-1097.2007.00226.x] [PMID: 18435612]
[17]
Mukhtar H, Elmets CA. Photocarcinogenesis: mechanisms, models and human health implications. Photochem Photobiol 1996; 63(4): 356-7.
[http://dx.doi.org/10.1111/j.1751-1097.1996.tb03040.x] [PMID: 8934734]
[18]
Moodycliffe AM, Ullrich SE. The role of cis-UCA in ultraviolet B radiation induced immunosuppression Delayed-Type Hypersensitivity (DTH) and Contact Hypersensitivity (CHS) responses. Photochem Photobiol 1995; 61(1): 535-41.
[19]
Kim J, Modlin RL, Moy RL, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995; 155(4): 2240-7.
[PMID: 7636270]
[20]
Katiyar S. Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin. Int J Oncol 2002; 21(6): 1213-22.
[http://dx.doi.org/10.3892/ijo.21.6.1213] [PMID: 12429970]
[21]
Hammerberg C, Duraiswamy N, Cooper KD. Reversal of immunosuppression inducible through ultraviolet-exposed skin by in vivo anti-CD11b treatment. J Immunol 1996; 157(12): 5254-61.
[PMID: 8955170]
[22]
Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K. Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases. Basic Clin Pharmacol Toxicol 2013; 112(4): 251-6.
[http://dx.doi.org/10.1111/bcpt.12032] [PMID: 23121838]
[23]
Gharagozloo M, Velardi E, Bruscoli S, et al. Silymarin suppress CD4+ T cell activation and proliferation: Effects on NF-κB activity and IL-2 production. Pharmacol Res 2010; 61(5): 405-9.
[http://dx.doi.org/10.1016/j.phrs.2009.12.017] [PMID: 20056147]
[24]
Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997; 89(8): 556-65.
[http://dx.doi.org/10.1093/jnci/89.8.556] [PMID: 9106644]
[25]
Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999; 163(12): 6800-9.
[PMID: 10586080]
[26]
Zhao J, Lahiri-Chatterjee M, Sharma Y, Agarwal R. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis 2000; 21(4): 811-6.
[http://dx.doi.org/10.1093/carcin/21.4.811] [PMID: 10753220]
[27]
Zhao J, Sharma Y, Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1? expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion. Mol Carcinog 1999; 26(4): 321-33.
[http://dx.doi.org/10.1002/(SICI)1098-2744(199912)26:4<321:AID-MC11>3.0.CO;2-9] [PMID: 10569809]
[28]
Wang H, Oo Khor T, Shu L, et al. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem 2012; 12(10): 1281-305.
[http://dx.doi.org/10.2174/187152012803833026] [PMID: 22583408]
[29]
Zi X, Mukhtar H, Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 1997; 239(1): 334-9.
[http://dx.doi.org/10.1006/bbrc.1997.7375] [PMID: 9345320]
[30]
Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 1999; 263(2): 528-36.
[http://dx.doi.org/10.1006/bbrc.1999.1398] [PMID: 10491326]
[31]
Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267(5205): 1782-8.
[http://dx.doi.org/10.1126/science.7892601] [PMID: 7892601]
[32]
Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 2002; 4(4): 655-63.
[http://dx.doi.org/10.1089/15230860260220166] [PMID: 12230878]
[33]
Ahmad N, Gali H, Javed S, Agarwal R. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun 1998; 247(2): 294-301.
[http://dx.doi.org/10.1006/bbrc.1998.8748] [PMID: 9642119]
[34]
Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: The state of the art. Molecules 2019; 24(11): 2155.
[http://dx.doi.org/10.3390/molecules24112155] [PMID: 31181687]
[35]
Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 1993; 18(3): 289-97.
[http://dx.doi.org/10.1007/BF03188811] [PMID: 8149949]
[36]
Wu JW, Lin LC, Tsai TH. Drug–drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009; 121(2): 185-93.
[http://dx.doi.org/10.1016/j.jep.2008.10.036] [PMID: 19041708]
[37]
Matveev AV, Koniaeva EI, Kurchenko VP, Shchekatikhina AS. Hepatoprotective properties of silymarin. Eksp Klin Gastroenterol 2011; 2(2): 130-5.
[PMID: 21560654]
[38]
Gillessen A, Schmidt HHJ. Silymarin as supportive treatment in liver diseases: A narrative review. Adv Ther 2020; 37(4): 1279-301.
[http://dx.doi.org/10.1007/s12325-020-01251-y] [PMID: 32065376]
[39]
Vaid M, Prasad R, Sun Q, Katiyar SK. Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS One 2011; 6(7): e23000.
[http://dx.doi.org/10.1371/journal.pone.0023000] [PMID: 21829575]
[40]
Chatterjee ML, Agarwal R, Mukhtar H. Ultraviolet B radiation-induced DNA lesions in mouse epidermis: an assessment using a novel 32P-postlabelling technique. Biochem Biophys Res Commun 1996; 229(2): 590-5.
[http://dx.doi.org/10.1006/bbrc.1996.1848] [PMID: 8954942]
[41]
Berardesca E, Cameli N, Cavallotti C, Levy JL, Piérard GE, de Paoli Ambrosi G. Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation. J Cosmet Dermatol 2008; 7(1): 8-14.
[http://dx.doi.org/10.1111/j.1473-2165.2008.00355.x] [PMID: 18254805]
[42]
Choo SJ, Ryoo IJ, Kim YH, et al. Silymarin inhibits melanin synthesis in melanocyte cells. J Pharm Pharmacol 2010; 61(5): 663-7.
[http://dx.doi.org/10.1211/jpp.61.05.0016] [PMID: 19406006]
[43]
Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol 2012; 12(1): 18.
[http://dx.doi.org/10.1186/1471-5945-12-18] [PMID: 23031632]
[44]
Uto T, Ohta T, Katayama K, Shoyama Y. Silibinin promotes melanogenesis through the PKA and p38 MAPK signaling pathways in melanoma cells. Biomed Res 2022; 43(2): 31-9.
[http://dx.doi.org/10.2220/biomedres.43.31] [PMID: 35431290]
[45]
Shie Morteza M, Hayati Z, Namazi N, Abdollahimajd F. Efficacy and safety of oral silymarin in comparison with oral doxycycline and their combination therapy in the treatment of acne vulgaris. Dermatol Ther 2019; 32(6): e13095.
[http://dx.doi.org/10.1111/dth.13095] [PMID: 31579978]
[46]
AlAnbari H, Sahib A, Raghif A. Effects of silymarin, N-acetylcysteine and selenium in the treatment of papulopustular acne. Oxid Antioxid Med Sci 2012; 1(3): 201-7.
[http://dx.doi.org/10.5455/oams.290912.or.019]
[47]
Singh RP, Agarwal R. Cosmeceuticals and silibinin. Clin Dermatol 2009; 27(5): 479-84.
[http://dx.doi.org/10.1016/j.clindermatol.2009.05.012] [PMID: 19695480]
[48]
Pientaweeratch S, Panapisal V, Tansirikongkol A. Antioxidant, anti-collagenase and anti-elastase activities of Phyllanthus emblica, Manilkara zapota and silymarin: an in vitro comparative study for anti-aging applications. Pharm Biol 2016; 54(9): 1865-72.
[http://dx.doi.org/10.3109/13880209.2015.1133658] [PMID: 26912420]
[49]
Mahmoodi-Nesheli M, Alizadeh S, Solhi H, Mohseni J, Mahmoodi-Nesheli M. Adjuvant effect of oral Silymarin on patients’ wound healing process caused by thermal injuries. Caspian J Intern Med 2018; 9(4): 341-6.
[PMID: 30510648]
[50]
Sharifi R, Rastegar H, Kamalinejad M, et al. Effect of topical application of silymarin (Silybum marianum) on excision wound healing in albino rats. Acta Med Iran 2012; 50(9): 583-8.
[PMID: 23165806]
[51]
Oryan A, Naeini AT, Moshiri A, Mohammadalipour A, Tabandeh MR. Modulation of cutaneous wound healing by silymarin in rats. J Wound Care 2012; 21(9): 457-64.
[http://dx.doi.org/10.12968/jowc.2012.21.9.457] [PMID: 22990400]
[52]
Tabandeh MR, Oryan A, Mohhammad-Alipour A, Tabatabaei-Naieni A. Silibinin regulates matrix metalloproteinase 3 (stromelysine1) gene expression, hexoseamines and collagen production during rat skin wound healing. Phytother Res 2013; 27(8): 1149-53.
[http://dx.doi.org/10.1002/ptr.4839] [PMID: 22976003]
[53]
Liu CH, Jassey A, Hsu HY, Lin LT. Antiviral activities of silymarin and derivatives. Molecules 2019; 24(8): 1552.
[http://dx.doi.org/10.3390/molecules24081552] [PMID: 31010179]
[54]
Evren E, Yurtcu E. In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin. Folia Microbiol (Praha) 2015; 60(4): 351-6.
[http://dx.doi.org/10.1007/s12223-015-0399-6] [PMID: 25937395]
[55]
Haddadi R, Shahidi Z, Eyvari-Brooshghalan S. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms. Phytomedicine 2020; 79153320.
[http://dx.doi.org/10.1016/j.phymed.2020.153320] [PMID: 32920285]
[56]
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69(13): 1777-98.
[http://dx.doi.org/10.2165/11317010-000000000-00000] [PMID: 19719333]
[57]
Pan Q, Ban Y, Xu LP, Yunchao B, Lijun Xu. Silibinin-Albumin nanoparticles: Characterization and biological evaluation against oxidative stress stimulated neurotoxicity associated with Alzheimer’s disease. J Biomed Nanotechnol 2021; 17(6): 1123-30.
[http://dx.doi.org/10.1166/jbn.2021.3038] [PMID: 34167626]
[58]
Antonietta Panaro M, Cianciulli A. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease. Curr Pharm Des 2012; 18(2): 200-8.
[http://dx.doi.org/10.2174/138161212799040574] [PMID: 22229581]
[59]
Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP. Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse. J Pineal Res 2011; 50(2): 97-109.
[PMID: 20964710]
[60]
Baluchnejadmojarad T, Roghani M, Mafakheri M. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: Involvement of estrogen receptors and oxidative stress. Neurosci Lett 2010; 480(3): 206-10.
[http://dx.doi.org/10.1016/j.neulet.2010.06.038] [PMID: 20600617]
[61]
Singh M, Sumien N, Kyser C, Simpkins JW. Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci 2008; 13(13): 1083-9.
[http://dx.doi.org/10.2741/2746] [PMID: 17981614]
[62]
Liu X, Chen W, Wang C, et al. Silibinin ameliorates depression/anxiety-like behaviors of Parkinson’s disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation. Physiol Behav 2021; 241: 113593.
[http://dx.doi.org/10.1016/j.physbeh.2021.113593] [PMID: 34536434]
[63]
Kosari-Nasab M, Shokouhi G, Ghorbanihaghjo A, Abbasi MM, Salari AA. Anxiolytic- and antidepressant-like effects of Silymarin compared to diazepam and fluoxetine in a mouse model of mild traumatic brain injury. Toxicol Appl Pharmacol 2018; 338(1): 159-73.
[http://dx.doi.org/10.1016/j.taap.2017.11.012] [PMID: 29175455]
[64]
Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007; 164(7) (Suppl.): 5-53.
[PMID: 17849776]
[65]
Grant JE, Odlaug BL, Madurai N, Cohen BM. Silymarin treatment of obsessive-compulsive spectrum disorders. J Clin Psychopharmacol 2015; 35(3): 340-2.
[http://dx.doi.org/10.1097/JCP.0000000000000327] [PMID: 25874918]
[66]
Lu P, Mamiya T, Lu L, et al. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav Brain Res 2010; 207(2): 387-93.
[http://dx.doi.org/10.1016/j.bbr.2009.10.024] [PMID: 19857526]
[67]
MacDonald-Ramos K, Michán L, Martínez-Ibarra A, Cerbón M. Silymarin is an ally against insulin resistance: A review. Ann Hepatol 2021; 23: 100255.
[http://dx.doi.org/10.1016/j.aohep.2020.08.072] [PMID: 32950646]
[68]
Vahabzadeh M, Amiri N, Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric 2018; 98(13): 4816-23.
[http://dx.doi.org/10.1002/jsfa.9115] [PMID: 29736939]
[69]
Goli F, Karimi J, Khodadadi I, et al. Silymarin attenuates ELMO-1 and KIM-1 expression and oxidative stress in the kidney of rats with type 2 diabetes. Indian J Clin Biochem 2019; 34(2): 172-9.
[http://dx.doi.org/10.1007/s12291-018-0735-0] [PMID: 31092990]
[70]
Chen Y, Chen L, Yang T. Silymarin nanoliposomes attenuate renal injury on diabetic nephropathy rats via co-suppressing TGF-β/Smad and JAK2/STAT3/SOCS1 pathway. Life Sci 2021; 271(1): 119197.
[http://dx.doi.org/10.1016/j.lfs.2021.119197] [PMID: 33577847]
[71]
Zholobenko A, Modriansky M. Silymarin and its constituents in cardiac preconditioning. Fitoterapia 2014; 97: 122-32.
[http://dx.doi.org/10.1016/j.fitote.2014.05.016] [PMID: 24879900]
[72]
Sheta NM, Elfeky YA, Boshra SA. Cardioprotective efficacy of silymarin liquisolid in isoproterenol prompted myocardial infarction in rats. AAPS PharmSciTech 2020; 21(3): 81.
[http://dx.doi.org/10.1208/s12249-019-1609-3] [PMID: 31974855]
[73]
Meng S, Yang F, Wang Y, et al. Silymarin ameliorates diabetic cardiomyopathy via inhibiting TGF-β1/Smad signaling. Cell Biol Int 2019; 43(1): 65-72.
[http://dx.doi.org/10.1002/cbin.11079] [PMID: 30489003]
[74]
Palit P, Mukhopadhyay A, Chattopadhyay D. Phyto‐pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID ‐19, based on its promising immunomodulatory, anti‐coagulant and anti‐viral property. Phytother Res 2021; 35(8): 4246-57.
[http://dx.doi.org/10.1002/ptr.7084] [PMID: 33817867]
[75]
Kumar P, Sharma DK, Ashawat MS. Traditional herbal medicines, newer herbs and other novel approaches integrated in herbal medicine for atopic dermatitis-a narrative review. Curr Drug Ther 2020; 15(3): 194-208.
[http://dx.doi.org/10.2174/1574885514666191018165209]
[76]
Kang JS, Yoon WK, Han MH, et al. Inhibition of atopic dermatitis by topical application of silymarin in NC/Nga mice. Int Immunopharmacol 2008; 8(10): 1475-80.
[http://dx.doi.org/10.1016/j.intimp.2008.06.004] [PMID: 18593606]
[77]
Mady FM, Essa H, El-Ammawi T, Abdelkader H, Hussein AK. Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis. Drug Des Devel Ther 2016; 10(1): 1101-10.
[PMID: 27022248]
[78]
Iraji F, Sharif Makhmalzadeh B, Abedini M, Aghaei A, Siahpoush A. Effect of herbal cream containing Fumaria officinalis and silymarin for treatment of eczema: A randomized double-blind controlled clinical trial. Avicenna J Phytomed 2022; 12(2): 155-62.
[PMID: 35614885]
[79]
Chavoshy F, Zadeh BSM, Tamaddon AM, Anbardar MH. Delivery and anti-psoriatic effect of silibinin-loaded polymeric micelles: An experimental study in the psoriatic skin model. Curr Drug Deliv 2020; 17(9): 787-98.
[http://dx.doi.org/10.2174/1567201817666200722141807] [PMID: 32703129]
[80]
Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine. Eur J Haematol 2013; 90(3): 202-9.
[http://dx.doi.org/10.1111/ejh.12061] [PMID: 23278124]
[81]
Gharagozloo M, Moayedi B, Zakerinia M, et al. Combined therapy of silymarin and desferrioxamine in patients with β-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol 2009; 23(3): 359-65.
[http://dx.doi.org/10.1111/j.1472-8206.2009.00681.x] [PMID: 19453758]
[82]
Moayedi Esfahani BAS, Reisi N, Mirmoghtadaei M. Evaluating the safety and efficacy of silymarin in β-thalassemia patients: a review. Hemoglobin 2015; 39(2): 75-80.
[http://dx.doi.org/10.3109/03630269.2014.1003224] [PMID: 25643967]
[83]
Capasso R, Aviello G, Capasso F, et al. Silymarin BIO-C®, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine 2009; 16(9): 839-44.
[http://dx.doi.org/10.1016/j.phymed.2009.02.007] [PMID: 19303749]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy